https://orcid.org/0000-0001-8140-6210
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson & Adrian P. Turner. (2023) Cost-effectiveness of tezepelumab in Canada for severe asthma. Journal of Medical Economics 26:1, pages 902-914.
Read now
Read now
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Read now
Javier Domínguez-Ortega, Daniel Laorden, Francisca Vílchez-Sánchez, David Bañas-Conejero & Santiago Quirce. (2023) Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. Journal of Asthma 0:0, pages 1-9.
Read now
Read now
Sara Alves, João Cavaleiro Rufo & José Crispim. (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 733-747.
Read now
Read now
Articles from other publishers (6)
Antonio Nieto, Zeinab A. El-Sayed, René Maximiliano Gómez, Elham Hossny, Wang Jiu-Yao, Ömer Kalayci, Mário Morais-Almeida, Wanda Phipatanakul, Paulo Marcio Pitrez, César Fireth Pozo Beltrán, Paraskevi Xepapadaki & Nikolaos G. Papadopoulos. (2023) Unanswered questions on the use of biologics in pediatric asthma. World Allergy Organization Journal 16:11, pages 100837.
Crossref
Crossref
Xuandao Liu, Tze Choong Charn & De-Yun Wang. (2023) Mepolizumab in chronic rhinosinusitis with nasal polyposis. Immunotherapy.
Crossref
Crossref
Wenjia Chen, Helen K. Reddel, J Mark FitzGerald, Richard Beasley, Christer Janson & Mohsen Sadatsafavi. (2023) Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials. Respiratory Research 24:1.
Crossref
Crossref
Tomas Abbott, Carlos Balmaceda, Paula Zamorano, Andres Giglio & Manuel Espinoza. (2023) Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile. Value in Health Regional Issues 35, pages 69-77.
Crossref
Crossref
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Maria D'Amato, Matteo Fontana & Nicola Facciolongo. (2021) The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. Multidisciplinary Respiratory Medicine 16.
Crossref
Crossref
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Francesco Livrieri & Nicola Facciolongo. (2021) Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab. Multidisciplinary Respiratory Medicine 16.
Crossref
Crossref